Adenosine: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 8: Line 8:
   
   
==Overview==
==Overview==
'''Adenosine''' (ADO) is a [[purine]] [[nucleoside]] comprising a [[molecule]] of [[adenine]] attached to a [[ribose]] sugar molecule ([[ribofuranose]]) [[functional group|moiety]] via a β-N<sub>9</sub>-[[glycosidic bond]].
Adenosine plays an important role in [[biochemistry|biochemical]] processes, such as energy transfer — as [[adenosine triphosphate]] (ATP) and [[adenosine diphosphate]] (ADP) — as well as in [[signal transduction]] as [[cyclic adenosine monophosphate]], cAMP. It is also an inhibitory neurotransmitter, believed to play a role in promoting sleep and suppressing arousal.
Adenosine also plays a role in regulation of blood flow to various organs through [[vasodilation]].<ref name="pmid15772334">{{cite journal|last=Sato|first=A|author2=Terata, K|author3=Miura, H|author4=Toyama, K|author5=Loberiza FR, Jr|author6=Hatoum, OA|author7=Saito, T|author8=Sakuma, I|author9= Gutterman, DD|title=Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease.|journal=American journal of physiology. Heart and circulatory physiology|date=April 2005|volume=288|issue=4|pages=H1633–40|pmid=15772334|doi=10.1152/ajpheart.00575.2004}}</ref><ref name="pmid9576114">{{cite journal|last=Costa|first=F|author2=Biaggioni, I|title=Role of nitric oxide in adenosine-induced vasodilation in humans|journal=Hypertension|date=May 1998|volume=31|issue=5|pages=1061–4|pmid=9576114|doi=10.1161/01.HYP.31.5.1061}}</ref><ref name="pmid1884445">{{cite journal|last=Morgan|first=JM|author2=McCormack, DG|author3= Griffiths, MJ|author4= Morgan, CJ|author5= Barnes, PJ|author6= Evans, TW|title=Adenosine as a vasodilator in primary pulmonary hypertension|journal=Circulation|date=September 1991|volume=84|issue=3|pages=1145–9|pmid=1884445|doi=10.1161/01.CIR.84.3.1145}}</ref>


==Category==
==Category==


==FDA Package Insert==
==FDA Package Insert<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = ADENOCARD (ADENOSINE) SOLUTION [ASTELLAS PHARMA US, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f0e32589-dad9-4887-8481-bcf7f6618466 | publisher =  | date =  | accessdate =  }}</ref>==


'''| [[Adenosine indications and usage|Indications and Usage]]'''
'''| [[Adenosine indications and usage|Indications and Usage]]'''

Revision as of 17:04, 11 March 2014


Adenosine
ADENOCARD®, ADENOSCAN® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Labels and Packages
Clinical Trials on Adenosine
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Synonyms / Brand Names: ADENOCARD®, ADENOSCAN®

Overview

Adenosine (ADO) is a purine nucleoside comprising a molecule of adenine attached to a ribose sugar molecule (ribofuranose) moiety via a β-N9-glycosidic bond.

Adenosine plays an important role in biochemical processes, such as energy transfer — as adenosine triphosphate (ATP) and adenosine diphosphate (ADP) — as well as in signal transduction as cyclic adenosine monophosphate, cAMP. It is also an inhibitory neurotransmitter, believed to play a role in promoting sleep and suppressing arousal.

Adenosine also plays a role in regulation of blood flow to various organs through vasodilation.[1][2][3]

Category

FDA Package Insert[4]

| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages

Mechanism of Action

References

  1. Sato, A; Terata, K; Miura, H; Toyama, K; Loberiza FR, Jr; Hatoum, OA; Saito, T; Sakuma, I; Gutterman, DD (April 2005). "Mechanism of vasodilation to adenosine in coronary arterioles from patients with heart disease". American journal of physiology. Heart and circulatory physiology. 288 (4): H1633–40. doi:10.1152/ajpheart.00575.2004. PMID 15772334.
  2. Costa, F; Biaggioni, I (May 1998). "Role of nitric oxide in adenosine-induced vasodilation in humans". Hypertension. 31 (5): 1061–4. doi:10.1161/01.HYP.31.5.1061. PMID 9576114.
  3. Morgan, JM; McCormack, DG; Griffiths, MJ; Morgan, CJ; Barnes, PJ; Evans, TW (September 1991). "Adenosine as a vasodilator in primary pulmonary hypertension". Circulation. 84 (3): 1145–9. doi:10.1161/01.CIR.84.3.1145. PMID 1884445.
  4. "ADENOCARD (ADENOSINE) SOLUTION [ASTELLAS PHARMA US, INC.]".